Opinion|Videos|October 8, 2024
Overview of DAPA ECHO Trial
Author(s)Javed Butler, MD, MPH, MBA
Key Takeaways
- The DAPA ECHO trial focused on dapagliflozin's effects on myocardial performance in nondiabetic heart failure patients.
- A randomized, double-blind, placebo-controlled design was employed, using echocardiography to assess cardiac function.
Javed Butler, MD, MPH, MBA, discusses the DAPA ECHO trial data presented at European Society of Cardiology Congress 2024, examining the effects of dapagliflozin on myocardial performance in patients with nondiabetic heart failure, including the study’s objective, design, methodology, results, and key clinical implications for the use of dapagliflozin in this population.
Advertisement
Video content above is prompted by the following:
- Discuss the data presented at European Society of Cardiology Congress 2024 for the DAPA ECHO trial in which the effects of dapagliflozin on myocardial performance were studied in patients with nondiabetic heart failure.
- What was the objective of this analysis?
- How was this study designed, and what methodology was used?
- What results were presented?
- Provide your key takeaways from this study. What are the key clinical implications in using dapagliflozin in patients with nondiabetic heart failure?
Advertisement
Related to this article
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
OCT patterns help distinguish MS, NMOSD, and MOGAD after optic neuritis, while timing and protocol shape MRI's diagnostic yield, experts say.
Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Advertisement
Advertisement
Trending on AJMC
1
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
2
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
3
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
4
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
5